Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System
January 04, 2023 12:00 ET
|
Beta Bionics, Inc.
CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief...
Beta Bionics Appoints Sean Saint as CEO and Board Member
August 15, 2022 16:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale. CONCORD, Mass., Aug. 15, 2022 ...
The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions
June 09, 2022 14:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas...
Pivotal Trial Results of the iLet® Bionic Pancreas to Be Presented at the ADA’s 82nd Scientific Sessions
June 01, 2022 05:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Roy W. Beck will moderate a session: The...
Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer
May 10, 2022 05:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer,...
The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes
April 30, 2022 04:00 ET
|
Beta Bionics, Inc.
The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population — 440 adults and children 6...
Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD
April 25, 2022 05:00 ET
|
Beta Bionics, Inc.
Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...
Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System
March 02, 2022 16:15 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
Beta Bionics Announces Closing of $57 Million Series C Financing
February 17, 2022 16:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The financing round was co-led by existing...
Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial
December 22, 2021 07:00 ET
|
Beta Bionics, Inc.
The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use.Not available for sale. The iLet® Bionic Pancreas is a pocket-sized, wearable...